You are here

Article Text

Article menu
Download PDFPDF
Aetiology/Harm
Systematic review
Metformin should not be contraindicated in patients with type 2 diabetes and mild to moderate renal impairment
  1. André J Scheen
  1. Division of Diabetes, Nutrition and Metabolic Disorders, University of Liège, Liège, UK
  1. Correspondence to Dr André J Scheen, Division of Diabetes, Nutrition and Metabolic Disorders, University of Liège, CHU Liège, Sart Tilman (B35), Liège B-4000, Belgium; andre.scheen{at}chu.ulg.ac.be

https://doi.org/10.1136/ebmed-2015-110184

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 2014;312:2668–75OpenUrlCrossRefPubMedWeb of Science.

    Context

    Metformin is considered the best initial treatment to lower glucose concentrations in patients with type 2 diabetes.1 However, as it is cleared by the kidneys, it may accumulate when renal function decreases, with the potential for exposure-dependent toxicity that could precipitate lactate accumulation. Chronic kidney disease (CKD) is a frequent scenario in type 2 diabetes, a condition that may challenge the use of many glucose-lowering agents.2 There is increasing evidence …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Commissioned; internally peer reviewed.